Li Liu

机构：Shihezi University, State Administration of Traditional Chinese Medicine of the People's Republic of China, Sichuan Academy of Traditional Chinese Medicine · ORCID：0000-0002-4490-2159

发表论文 100 篇 · 总被引 2119 次 · h-index 29

代表论文

• Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). (2023 · Journal of Clinical Oncology · 被引 36)
• The impact of diabetes on Sepsis-induced cardiomyopathy (2025 · Diabetes Research and Clinical Practice · 被引 9)
• Efficacy and safety of PD‐1 inhibitor alone or combined with chemotherapy in patients with relapsed or refractory extranodal natural Killer/T cell lymphoma: A retrospective study (2022 · Hematological Oncology · 被引 8)
• Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial (2024 · Annals of Hematology · 被引 7)
• Harnessing local and system immune profiling delineating differential responders to first-line sintilimab (anti-PD-1 antibody) combined with chemotherapy in extensive-stage small cell lung cancer: an exploratory biomarker analysis of a phase II study (2025 · Signal Transduction and Targeted Therapy · 被引 6)
• A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (2022 · Blood · 被引 6)